Our Science

Our pipeline

Innovation that advances cancer care

Seagen is developing a new generation of targeted, empowered treatments to advance cancer care. We’ve designed our pipeline with patients in mind, focusing on therapies that have the potential to address significant unmet medical needs.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Seagen Overview Pipeline

Program

Phase

Phase

Brentuximab vedotin (ADCETRIS®)

Learn More
Phase 1
Phase 2
Phase 3

R/R Diffuse large B-Cell lymphoma

SGN35-31: + lenalidomide, rituximab

1L Hodgkin lymphoma (HL)

SGN35-27: + nivolumab, doxorubicin and dacarbazine

1L HL or PTCL (unfit for combination chemotherapy)

SGN35-15: Monotherapy

R/R HL and PTCL

SGN35-28: Retreatment

R/R HL (pediatrics)

CheckMate 744: + nivolumab

1L PTCL (< 10% CD30 expression)

+ cyclophosphamide, doxorubicin and prednisone

R/R Metastatic solid tumors

pembrolizumab post PD-1

Enfortumab vedotin-ejfv (PADCEV®)

Learn More
Phase 1
Phase 2
Phase 3

1L Locally advanced or metastatic urothelial cancer

EV-302: + pembrolizumab, +/- chemotherapy

Locally advanced or metastatic urothelial cancer*

EV-301: Post PD(L)-1 and post platinum chemotherapy

1L Muscle invasive bladder cancer

EV-303/KEYNOTE-905: + pembrolizumab, cisplatin ineligible

Muscle invasive bladder cancer

EV-304/KEYNOTE-B15: + pembrolizumab, cisplatin eligible

Locally advanced or metastatic urothelial cancer*

EV-201: Cohort 2 post PD(L)-1, platinum naïve and cisplatin ineligible

1L/2L Locally advanced or metastatic urothelial or muscle-invasive cancer

EV-103: +/- pembrolizumab

Locally advanced or metastatic solid tumors

EV-202: Monotherapy

1L Muscle invasive bladder cancer

EV-103: +/- pembrolizumab

Tucatinib (TUKYSA®)

Learn More
Phase 1
Phase 2
Phase 3

HER2CLIMB-02 –  Metastatic HER2+ breast cancer

HER2CLIMB-02: + T-DM1

High risk HER2+ breast cancer

CompassHER2 RD**

HER2+ metastatic breast cancer

+ trastuzumab deruxtecan

R/R HER2+ metastatic colorectal cancer

MOUNTAINEER: + trastuzumab

HER2+ gastroesophageal cancer 2L

MOUNTAINEER-02: + trastuzumab, ramucirumab and chemotherapy

Metastatic solid tumors HER2 alterations

+ trastuzumab, +/- fulvestrant

1L HER2+ gastric cancer

+ trastuzumab, oxaliplatin

Tisotumab vedotin

Learn More
Phase 1
Phase 2
Phase 3

2L/3L Metastatic/recurrent cervical cancer

innovaTV 301: Monotherapy

2L/3L Recurrent or metastatic cervical cancer†‡

innovaTV 204: Monotherapy

1L/2L Recurrent or metastatic cervical cancer

innovaTV 205: + other anti-cancer agents

Locally advanced solid tumors

innovaTV 206 (Japan only)

R/R Metastatic solid tumors

innovaTV 207: Monotherapy

Platinum-resistant ovarian cancer

innovaTV 208: Monotherapy

Ladiratuzumab vedotin

Learn More
Phase 1
Phase 2
Phase 3

1L Metastatic triple-negative breast cancer

+ pembrolizumab

R/R Metastatic solid tumors

Monotherapy

R/R Metastatic breast cancer (HR+/HER2-)

Monotherapy

SEA-BCMA

Phase 1
Phase 2
Phase 3

R/R Multiple myeloma

+/- dexamethasone

SEA-CD40

Phase 1
Phase 2
Phase 3

R/R Pancreatic cancer

+/- pembrolizumab, gemcitabine, nab-paclitaxel

SGN-CD228A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SEA-CD70

Phase 1
Phase 2
Phase 3

R/R MDS/AML

Monotherapy

SEA-TGT

Phase 1
Phase 2
Phase 3

R/R Solid tumors and lymphoma

+/- pembrolizumab

SGN-B6A

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SGN-STNV

Phase 1
Phase 2
Phase 3

R/R Solid tumors

Monotherapy

SGN-CD30C

Phase 1
Phase 2
Phase 3

Lymphoma

1L=frontline/first-line, 2L=second-line, R/R=relapsed/refractory, PTCL=peripheral T-cell lymphoma.

*Enrollment Complete
Pivotal Trial
Top-line Data Reported

Request additional information

Request additional information about an investigational therapy or report an adverse event.

Contact Medical Information